Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induced P. vivax Infection for Parasite Bank
NCT05095272Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2022
- Primary completion
- Jun 2022
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HMPBS02-Pv in malaria, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: P. Vivax Blood Collection at 11 days. Started Feb 2022; status: completed.
02
Drugs
HMPBS02-Pv
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05095272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05095272.